New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
Rhea-AI Summary
Nanox (NASDAQ:NNOX) will present new clinical data on its Nanox.AI cardiac solution HealthCCSng at the SCCT 2026 meeting in San Diego, July 9-12, 2026.
Highlights include initial multi-site AI INFORM trial results, a coronary calcium agreement analysis, and a sponsored session on aortic valve calcification.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
Market reaction: NNOX -6.06% on SCCT 2026 cardiac AI clinical data
On the day this news was published, NNOX declined 6.06%, reflecting a notable negative market reaction. Argus tracked a trough of -6.4% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $87.77M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Q1 2026 earnings | Negative | -44.0% | Revenue growth but large losses and going-concern warning drove a steep decline. |
| Jun 11 | Earnings date notice | Neutral | +3.2% | Scheduled Q1 2026 results release and conference call announcement. |
| Jun 02 | Peru distribution deal | Positive | -1.5% | Exclusive Peruvian distribution agreement for Nanox.ARC under a capex model. |
| May 04 | U.S. distribution deal | Positive | +8.1% | NuvioDx agreement to expand Nanox.ARC deployments across U.S. clinical sites. |
| Apr 23 | U.S. distribution deal | Positive | -14.3% | Radiology Oncology Systems deal to expand Nanox.ARC adoption in U.S. settings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced volatile and sometimes contradictory reactions, including a sharp selloff on weak Q1 2026 results but mixed responses to commercial distribution agreements.
Regulatory & Risk Context
Short interest appears elevated, implying positioning that can amplify volatility in either direction if sentiment shifts or liquidity tightens.
An active Form F-3 shelf allows the company to sell securities from time to time, which could introduce future equity or debt issuance and potential shareholder dilution if utilized.
Key Terms
fda-cleared regulatory
coronary artery calcium medical
aortic valve calcification medical
chest ct technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New SCCT abstracts from Brigham and Women’s Hospital highlight the performance and clinical utility of Nanox.AI’s FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its potential role in supporting guideline-directed preventive care.
From incidental finding to clinical action: the AI INFORM randomized trial highlights how AI-detected coronary calcium may help clinicians identify opportunities for preventive lipid-lowering therapy.
Nanox.AI Sponsors SCCT Scientific Session, “From Missed Finding to Missed Opportunity: Aortic Valve Calcification on Chest CT,” Featuring Ofir Koren, MD, Cedars-Sinai Medical Center, on Sunday, July 12, at 7:30 am
PETACH TIKVA, Israel, July 07 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, or the “Company” NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that data from studies featuring Nanox.AI's AI cardiac solution (HealthCCSng) will be presented at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT), taking place July 9-12, 2026 in San Diego, California.
Nanox.AI’s FDA-cleared solutions analyze routine medical CT scans, performed for any clinical indication, to help identify patients with asymptomatic or undetected findings associated with chronic cardiac, liver, and bone conditions, enabling proactive preventive care management:
- AI Cardiac solution (HealthCCSng)
- AI Bone solution (HealthOST)
- AI Liver solution (HealthFLD)
Nanox’s SCCT 2026 data will feature initial findings from the multi-site AI INFORM clinical trial, as well as a separate multi-site analysis of agreement between HealthCCSng and expert visual assessment of coronary artery calcium.
The studies are being presented by members of Brigham and Women’s Hospital, Massachusetts General Hospital, University of Texas Southwestern Medical Center and other medical institutions.
The abstracts include:
“Artificial Intelligence Detection Of Incidental Coronary Artery Calcium To Enhance Cardiovascular Disease Prevention: The AI INFORM Trial” (Abstract 614; Daniel M. Huck, MD, MPH; Poster Session 20-Plaque Imaging) and “Agreement Between AI-detected Coronary Artery Calcium And Expert Visual Assessment: A Multi-site Analysis” (Abstract 565; Camila V. Blair, MD; Poster Session 16-Non contrast cardiac CT: Coronary calcium). Both posters will be presented on July 11, 2026 at 10:55 AM PDT.
Separately, Nanox.AI is also sponsoring a scientific session titled “From Missed Finding to Missed Opportunity: Aortic Valve Calcification on Chest CT,” on Sunday, July 12, 2026, at 7:30 a.m., featuring Ofir Koren, MD, of Cedars-Sinai Medical Center. The session will discuss the clinical significance of aortic valve calcification identified on routine chest CT scans and ongoing research in this area. Any referenced technology is currently under development and is not commercially available or cleared for clinical use.
Representatives of Nanox.AI will be available throughout SCCT 2026 for discussions of clinical data and collaboration opportunities. Schedule a meeting here
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.
About Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, statements regarding: the Company’s expected commercialization efforts, business strategy and long-term growth opportunities; the expected timing, pace, extent and success of deployments, installations, activations and utilization of Nanox.ARC systems, including under the Nanox Imaging Network; the anticipated benefits, timing and extent of activity under existing commercial, distribution and strategic agreements, including contemplated deployments of hundreds of systems over the coming years; the potential outcome, scope and timing of the evaluation of strategic alternatives relating to the Company’s South Korea operations, including an expanded restructuring, a potential sale, wind-down or closure of all or part of such operations; the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; and (xii) risks related to litigation which may result in significant liability and damage to the Company’s reputation. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
